| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Tovetumab Basic information |
| Product Name: | Tovetumab | | Synonyms: | Tovetumab;Research Grade Tovetumab(DHD16102);Research Grade Tovetumab | | CAS: | 1243266-04-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tovetumab Structure]() |
| | Tovetumab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Tovetumab Usage And Synthesis |
| Uses | Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC)[1][2]. | | in vivo | Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].
| Animal Model: | Cynomolgus monkey[1] | | Dosage: | 0.6, 6.0, and 60 mg/kg | | Administration: | Intravenous injection (i.v.) | | Result: | Induced > 100- fold increases in circulating concentrations of PDGF-AA. |
| Animal Model: | U118 glioma xenografts (CB17 SCID)[2] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), twice per week. | | Result: | Produced 101% inhibition of tumor growth. |
| | IC 50 | PDGFRα | | References | [1] Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23(1):4. DOI:10.1208/s12248-020-00523-3
[2] Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83(6):1247-56. DOI:10.1124/mol.112.084079 |
| | Tovetumab Preparation Products And Raw materials |
|